FDA approves Tekturna HCT as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent
Links shared publicly online about this topic.
- 1,881total visits
FDA approves Tekturna HCT as initial treatment in patients unlikely to achieve their blood pressure goal with a single agent
Basel, July 21, 2009 - The US Food and Drug Administration (FDA) has approved Tekturna HCT (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals. Tekturna HCT is a single-pill combination of Tekturna (aliskiren), the first and only approved direct renin inhibitor[1], and the diuretic hydrochlorothiazide (HCTZ), one of the most commonly used high blood pressure medications[5].
View full resource at novartis.com
Tags: Heart Disease, High Blood Pressure, Drug, FDA
Most Recently Shared on July 21, 2009 at 1:43 pm By:
FDA approves Tekturna HCT® as initial treatment in pts unlikely to achieve blood pressure goal with a single agent http://bit.ly/AfNcA
Advertisement
